Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping channels, simplifying integration across marketplaces and social platforms. Firmly also launched Ask Agent, a conversational shopping tool that enables merchants to offer AI-powered product discovery and checkout on their websites with minimal setup. This funding will accelerate global growth, helping merchants sell through multiple AI and digital channels while maintaining control over customer data and transactions.
Firmly's recent $15 million Series A funding and new AI shopping tool launch provide context for technology sector trends. For readers following Technology-sector US stocks on Pluang, here is the market snapshot as of Nov 05, 2026 20:52 WIB: out of 150 priced stocks, 46 rose and 101 fell. Notable movers include APPN at USD 58.00 with a 1-day change of +16.42% and 100% sell order activity, FSLY at USD 17.62 down 16.23%, and RELY at USD 23.15 down 14.51%, with typical hold times ranging from 20 to 54 days.
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
Dune has completed a SOC 2 Type II examination with no exceptions, providing institutional clients with verified assurance of its data security standards. This milestone comes as tokenized real-world assets doubled to $32.6 billion and stablecoin mar...
Northern Discovery Metals has finalized the acquisition of a 100% interest in the Cibola copper-gold project in British Columbia from Orogen Royalties. The project covers about 3,567 hectares near Houston, BC, in a region known for porphyry copper de...
Opus Genetics has finished dosing the higher-dose Cohort 2 in its Phase 1/2 trial of OPGx-BEST1, a gene therapy for BEST1-related inherited retinal diseases like Best vitelliform macular dystrophy and autosomal recessive bestrophinopathy. Cohort 2 en...
